Yohimbine derivatives are disclosed having modification of the C-16 carboxyl group to include a sidechain and where the resulting derivative does not possess a second yohimbine pharmacophore (i.e., the compound is not a yohimbine dimer). The yohimbine derivatives of the present invention are preferably characterized by selective activity as α2c-AR antagonists. Use of the compounds, or pharmaceutical composition containing them, for treating or preventing an α2c adrenergic receptor mediated condition or disorder, and for antagonizing activity of an α2c adrenergic receptor are also disclosed.
优匹定衍
生物被披露,其将C-16羧基改变为包含一个侧链,并且所得到的衍
生物不具有第二个优匹定药效团(即,该化合物不是优匹定二聚体)。本发明的优匹定衍
生物最好具有作为α2c-AR拮抗剂的选择性活性。还披露了利用这些化合物或含有它们的药物组合物来治疗或预防α2c
肾上腺素能受体介导的疾病或疾病,并拮抗α2c
肾上腺素能受体活性的用途。